Thrombolytic Science
TSI is a privately-held vascular medicine and biotechnology company currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for stroke and other thrombotic diseases. TSI’s technology is based upon pioneering earlier work on pro-urokinase (proUK) by its cofounders. The primary component of TSI’s thrombolytic therapy is a rationally designed mutant of proUK.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Thrombolytic Science
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
Showing 1 of 3 verified contacts
Top roles at Thrombolytic Science
3 distinct titles indexed · top 3 shown.
- 1physician, professor of medicine, harvard medical school
- 1president & chief executive officer, co-founder & board member
- 1technical recruiter
Sign up to unlock all 3 contacts at Thrombolytic Science
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Thrombolytic Science
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.